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High-Coverage Whole-Exome 
Sequencing Identifies Candidate 
Genes for Suicide in Victims with 
Major Depressive Disorder
Dóra Tombácz1,2, Zoltán Maróti3, Tibor Kalmár  3, Zsolt Csabai1, Zsolt Balázs1, Shinichi 
Takahashi2, Miklós Palkovits4, Michael Snyder2 & Zsolt Boldogkői1
We carried out whole-exome ultra-high throughput sequencing in brain samples of suicide victims who 
had suffered from major depressive disorder and control subjects who had died from other causes. This 
study aimed to reveal the selective accumulation of rare variants in the coding and the UTR sequences 
within the genes of suicide victims. We also analysed the potential effect of STR and CNV variations, 
as well as the infection of the brain with neurovirulent viruses in this behavioural disorder. As a result, 
we have identified several candidate genes, among others three calcium channel genes that may 
potentially contribute to completed suicide. We also explored the potential implication of the TGF-β 
signalling pathway in the pathogenesis of suicidal behaviour. To our best knowledge, this is the first 
study that uses whole-exome sequencing for the investigation of suicide.
Close to 20 million suicides are attempted annually worldwide, of which more than one million are completed1. 
Suicide is the 10th leading cause of mortality in the world, which supports the importance of better defining the 
genetic causes and social basis of this disorder, and to identify individuals at risk. Suicide is a complex behaviour, 
determined by the interaction between proximal and distant risk factors. The proximal factors include recent life 
events, substance abuse and mental disorders, such as major depressive disorder (MDD), bipolar disorder and 
schizophrenia. The most important distal factors are the genetic and epigenetic factors, family history, early-life 
adversity and personality2, 3 The most common underlying disorder is MDD, which is the leading cause of disa-
bility worldwide4; more than 50% of suicide victims suffer from this disease, which increases the risk of suicide 
by up to twentyfold5. A number of studies have shown a familial accumulation of suicidal behaviour including 
suicide completion and attempt6.Twin and adoption studies have revealed that the heritability of suicide ranges 
between 30–55%7.
According to the current consensus, depression is etiologically a heterogeneous disease with overlapping 
causal pathways8, but logically, completed suicide with MDD may have a much less diverse genetic back-
ground. The heritable components of suicidal behaviour have until recently only been investigated either by 
hypothesis-driven research that focuses on preselected candidate genes9–11, or by the comparison of the frequen-
cies of common genetic variants12, 13. Neurobiological evidence implicates the dysfunction of the HPA axis14, 15, as 
well as the serotonergic16–18, the dopaminergic19, 20 and other systems in suicidality.
The candidate gene approach has to date yielded very few results with general consensus. Genome-wide 
association studies (GWASs), in spite of their large sample sizes have not explored any association signals in 
depression21, 22, which may be in connection with the heterogeneous genetic background of MDD or it may also 
be possible that the causative genetic factors of depression could lie outside of the scope of these studies. In con-
trast to candidate gene and GWASs, whole-exome studies (WES) or whole-genome studies (WGS) allow for the 
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comparison of genomes with base pair precision, and are therefore capable of revealing rare genetic variants that 
potentially play a causative role in suicidal behaviour. Additionally, WES and WGS techniques allow the exam-
ination of the potential pathogenic role of expansion of short tandem repeats (STRs), copy number variations 
(CNV) and infection by viruses.
Until recently, the common disease-common variant hypothesis has been the ruling concept, and has been 
the theoretical basis for GWAS. However, it turns out that common alleles can explain only a fraction of the 
heritability of common diseases23. Today, we are witnessing the emergence of the common disease–rare variant 
hypothesis24, which proposes that rare variants may also be an underlying factor in common diseases, meaning 
that the same common disease can have different rare causative variants in different individuals. WES analysis is 
able to identify novel rare genetic variants, as well as common variants associated with monogenic25 and complex 
diseases26. WES platforms can be especially successful in the identification of heterogeneous single-gene disorders 
(umbrella diseases), which can be caused by multiple high-penetrance rare genetic factors.
In principle, suicide may be a heterogeneous Mendelian phenotype or, it may also be possible that genes 
that are known to cause single gene disorders may also confer risk of suicide in a certain percentage of patients. 
Indeed, an investigation of the medical records of 110 million patients demonstrated an association between 
monogenic disorders and complex diseases, such as MDD, bipolar disorder, and schizophrenia27.
In this study, we applied an Illumina HighSeq platform-based high-coverage WES technique, which, in addi-
tion to the exons, allows the determination of 5′- and 3′-UTRs, promoters to a certain length, along with off-target 
sequences, such as introns, intergenic regions and infecting viruses. The limitation of the WES platform is that 
it is not able to study potential factors located in the inter-genomic or deep intronic regions. However, it is esti-
mated that 85% of penetrant disease-causing mutations reside in the coding regions of the genome28; therefore 
WES analysis has the potential to uncover the causes of rare variants of both homogeneous and heterogeneous 
monogenic disorders. In our study, all suicide victims suffered from MDD. We analysed the Hungarian popula-
tion, which is known to have a high incidence of suicide29. To our best knowledge, until now no WES platform has 
been used for studying suicide, but a low-coverage WGS study on MDD has recently been published30.
Results
Analysis of biallelic variants. Based on the hypothesized molecular basis (risk/protective alleles and rare 
variants), we carried out specific bioinformatic analyses to investigate the potential genetic factors contributing 
to suicide. We assumed that within the suicide cohort the random distribution of high impact (HI) mutations 
throughout a gene represents loss-of-function variants, whereas an accumulation of mutations at specific regions 
SAMPLE 
COUNT
NUMBER 
OF 
VARIANTS GENOMIC RANGE GENE REGION SUICIDE SAMPLE ID
7 1 19:535931-536148 CDC34* UPSTREAM Y482,Y375,Y393,Y426,Y532,Y787,Y919
6 1 5:111091613-111091736 NREP* SPLICE BIB82,Y316,Y331,Y482,Y516,Y558
6 4 2:242666998-242668839 ING5* 3' UTR Y166,Y292,Y591,Y724,Y988,Y787
5 4 11:117156433-117160295 BACE1 3' UTR BrA206,Y331,Y645,Y919,Y292
5 2 22:23505688-23506663 RAB36 3' UTR Br333,Y331,Br857,Y166,Y558
5 5 1:118507671-118509205 SPAG17* 3' UTR Y375,Y393,Y421,Y520,Y532
5 5 2:240504919-240507676 ENST00000358775* 3' UTR BIB82,Y375,Y426,Y532,Y724
4 4 X:17750592-17754159 NHS 3' UTR Y426,Y516,Y532,Y919
4 1 15:20875075-20875135 NBEAP1* INTRON BIB82,BrA206,Y724,Y919
4 1 5:147649533-147649718 SPINK13 INTRON Y331,Y393,Y532,Y591
4 1 20:2732322-2732689 EBF4 UPSTREAM BIB82,Y393,Y516,Y558
4 2 3:130282083-130282518 COL6A6* EXONIC Y166,Y292,Y724,Y482
4 2 12:42475627-42481688 GXYLT1* 3' UTR Y166,Y591,Y919,Y787
4 3 2:210884434-210885839 RPE 3' UTR Br857,Y919,Y558,Y591
4 3 7:139246399-139257490 HIPK2* 3' UTR Y166,Y787,Y292,Y516
4 3 9:87486857-87492822 NTRK2 3' UTR Br333,Y375,Y426,Y645
4 4 18:11852188-11853806 GNAL 3' UTR Br857,Y292,Y421,Y787
4 4 1:3350379-3355244 PRDM16 3' UTR Y292,Y421,Y426,Y988
4 4 7:141356464-141362505 KIAA1147* 3' UTR Br333,Y292,Y375,Y645
4 4 4:164445811-164449937 MARCH1* 3' UTR Y166,Y516,Y532,Y988
4 4 15:67482895-67487583 SMAD3 3' UTR Br857,BrA206,Y421,Y532
Table 1. Genomic region-dependent accumulation of rare variants in suicide samples.This table lists the 
genomic regions in which at least 4 suicide samples had rare variant(s). The SAMPLE COUNT column contains 
the number of suicide victims with rare variants in the same gene, the NUMBER OF VARIANTS column 
contains the number of individual variants within the gene, the GENOMIC RANGE column shows the GRCh37 
start/end coordinates of the region, the GENE column contains the name of the gene, the REGION column 
contains the type of the genomic region, the SAMPLE ID column contains the suicide sample IDs with the rare 
variant in the given genomic regions. *denotes genes without disease association in MalaCards and OMIM.
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GENE CHR POS REF ALT CONSEQUENCE SAMPLE ID
MRPL45* 17 36478478 A C stop-loss BrA206,Y426
CACNA2D4 12 2024019 C A splice donor & intron Y516
OTOGL 12 80764471 T C splice donor & intron Y591
CWC27 5 64084836 C T stop-gain Y520
SPATA31C2* 9 90748568 T A splice acceptor & intron Y558
RGL4* 22 24041028 CAGCTACAAGCTGT C splice acceptor & splice region & intron & non-coding transcript exon Y331
PMCH 12 102591506 AAGTT A frameshift Y532
TRIM15* 6 30131613 CG C frameshift Br333
CEP85L 6 118880200 T G stop-gain Y166
NME1 17 49231585 G C splice acceptor & intron Y166
ZNF718* 4 60294 T C stop-loss & splice region Y375
CENPC 4 68385221 C G splice acceptor & intron Y724
CDK14* 7 90338857 T C start-loss Y591
RAB3GAP2 1 220363490 T C splice acceptor & intron Y292
PMM2 16 8900171 A G splice acceptor & intron Y375
TMPRSS11F* 4 68919659 G A stop-gain Y919
SURF4* 9 136233553 T A splice acceptor & intron Y482
CKB 14 103988441 G A stop-gain Y919
PCYOX1L* 5 148742545 CAA C frameshift Y532
MIXL1 1 226413300 T A stop-gain Y516
D2HGDH 2 242688420 CCCTGTGAGGATGGT C splice donor & splice region & intron Y724
PSKH1* 16 67961717 C T splice acceptor & intron Y316
BRMS1L 14 36333074 A G splice acceptor & intron Y919
ST14 11 130058476 AT A frameshift Y591
STRA8* 7 134925307 CA C frameshift Y919
ARRDC2* 19 18120687 C T stop-gain Y292
BOD1L1* 4 13629016 GC G frameshift Y292
H2AFZ* 4 100871387 T C splice donor & intron Y426
CFAP70* 10 75056798 A G splice donor & intron Y166
SKOR2* 18 44746383 T C splice acceptor & intron Y558
PRKAG2 7 151573704 A G start-loss Y316
ADRA1A 8 26636945 C A stop-gain & splice region Y516
TMEM132C* 12 129189800 G T stop gain Y421
S100A13* 1 153600595 A AC splice donor & intron Y724
DLG2 11 83191415 G A stop-gain & splice region Y331
PCSK5 9 78790138 AAATGGAATGGAATGAA ATGGAATGGAATGGAATGG A frameshift Y421
C1orf226* 1 162353052 CCA C frameshift Y426
EPS15 1 51946947 GTC G frameshift Y482
WDR12* 2 203749260 T C splice acceptor & intron Y375
TMA16* 4 164415989 G A splice donor & intron Y645
LOC100507443* 2 208993176 C CA frameshift Y516
CES4A* 16 67035297 TC T frameshift Y558
NUDCD3* 7 44530037 G GCT frameshift Y724
TP53RK 20 45315393 T C stop-loss Y331
RABGGTA 14 24737761 C T stop-gain Y919
UBE2E3* 2 181846846 AC A frameshift Y166
MPDZ 9 13140066 A G start-loss Br857
TNFRSF11B 8 119936822 G A stop-gain Y919
ABI1 10 27054244 TC T frameshift & splice region Y919
HAPLN1 5 82940440 TGA T frameshift BrA206
MRAP2 6 84772679 C CT frameshift Y591
CAND2* 3 12854548 G T stop-gain Y393
CACNA1C 12 2659708 A C splice acceptor & intron Y988
KRTAP2-4* 17 39221826 G GA frameshift BrA206
SORL1 11 121502724 G C splice acceptor & intron Y520
Continued
www.nature.com/scientificreports/
4Scientific REpoRTS | 7:  7106 | DOI:10.1038/s41598-017-06522-3
within a gene is supposed to indicate a gain-of-function mechanism through altering the operation of protein 
domains or regulatory sequences. We assumed that genes having HI common variants with MAF higher than 
the incidence of suicide cannot be accountable in the loss-of-function model, and so we excluded them from the 
analysis.
Analysis of region-specific accumulation of rare genetic variants. Gene function can be changed 
either by domain-specific mutations of the exonic regions resulting in altered protein function, or by muta-
tions in the regulatory motifs that could lead to abnormal level or pattern of gene expression. Contrary to the 
loss-of-function mutations, which can be randomly distributed along the entire gene, gain-of-function mutations 
are supposed to be localized in well-defined regions. In the examined 594,910 genomic regions we identified 
14,393 rare (AF < 1/5,000) variants that were not present in the Hungarian controls. The vast majority of the 
genomic regions contained no rare variants, 13,459 regions had only a single rare variant, in 808 regions 2, in 101 
regions 3, and in 21 regions, at least 4 suicide samples had rare variants in the same genomic region (Table 1).
We identified a single exonic location (in COL6A6 gene encoding the alpha 6 chain of collagen type VI, 
which plays a role in axon guidance) that accumulated rare variants in more than 17% of the suicide cohort. 
Intriguingly, COL6A6 was also identified as a candidate gene in our recessive loss-of-function analysis (see 
below). Among the related pathways of this cell-binding protein are the interleukin and GM-CSF signalling and 
NCAM1 interactions31.
Additionally, we identified 20 non-exonic (putative regulatory) regions that contained rare variants in ~20% 
of suicide patients, which may contribute to the completed suicide. We must note that some of the variants in the 
list may be population-specific low MAF variants that were obtained because of the high number (594,910) of 
genomic regions examined in this study and the random selection of the individuals. The GNAL gene has been 
shown to contribute to schizophrenia32, the BACE1 gene is a candidate for Alzheimer’s disease33, while the NREP 
gene is associated with neural regeneration. In this analysis, we observed the highest enrichment in the CDC34 
with 7 sample counts; this gene encodes an ubiquitin-conjugating enzyme playing a role in the control of cell 
cycle34. For the detailed list of the 64 individual variants, see Table S1.
Together, this part of our study revealed that there is no such gene in our cohort that could alone be account-
able for causing suicide by domain-specific exonic alterations, but some rare alleles may play a non-exclusive 
causative role in this disorder.
Identification of putative dominant loss-of-function rare variants. We identified 61 different pro-
tein damaging mutations (19 frameshift, 21 splice site, 3 start-loss, 5 stop-loss, and 13 stop-gain mutations), which 
were found exclusively in the suicide patients (Table 2). Only a single HI mutation (stop-loss, gene MRPL45) was 
present in two suicide individuals. MRPL45, encoding a component of the large subunit of the mitochondrial 
ribosome, is a Y-linked gene that if truly proves to be a risk factor, may explain the higher incidence of males for 
committing suicide.
From this cohort, 31 had no disease association in MalaCards and OMIM (Table 2). We found a male specific 
(Y chromosome) HI mutation in the TGIF2LY gene, too. Among the remaining 30 disease-associated genes, eight 
genes have been shown to contribute to neurological disorders. Note that CACNA1C encode a calcium ion chan-
nel, such as we found in the analysis of common variant risk factors (CACNA1B). Intriguingly, a genome-wide 
analysis has also revealed that CACNA1B along with the CACNA1A gene play a shared effect on 5 major psy-
chiatric disorders, including MDD35. In this part of our study, we identified another calcium channel protein, 
CACNA2D4, which has been shown to play a role in the pathogenesis of bipolar disorder36.
In the second part of this study, we broadened our scope by including MI variants in the analysis. We selected 
genes in which at least two suicide samples had a rare variant (AF < 1/5,000 in databases; and so, it is not found in 
the Hungarian controls). We identified altogether 42 genes with 86 possibly protein damaging mutations found 
exclusively in the individuals who committed suicide (Table 3). The DOT1L and TTC28 genes were detected in 
four samples. None of these genes has been associated with any diseases so far. For five genes (TTC34, SCLY, 
SPHKAP, SOGA1, YES1) we found MI rare variants in 3 samples, all the other genes had only MI mutations 
in two samples (Table 3). In this cohort, seven genes have already been associated with neurological disorders 
GENE CHR POS REF ALT CONSEQUENCE SAMPLE ID
LRRC37A4P* 17 43585907 T C splice acceptor & intron Y482
PEMT 17 17409148 T G stop-loss Y645
RBMXL2 11 7110854 GC G frameshift Br333
ZNF646* 16 31091705 C T stop-gain Br857
RBM12B* 8 94752787 T A stop-loss Y787
TGIF2LY* Y 3447816 GCC G frameshift Y645
Table 2. Putative dominant loss-of-function candidate genes where at least one sample had a rare protein 
disruptive variant in the suicide samples.Each genetic variant was a heterozygote. GENE is the name of 
gene; CHR and POS shows the GRCh37 coordinate of the variant, REF/ALT columns shows the reference 
and alternate alleles, CONSEQUENCE is the type of the protein disruption, and the SAMPLE ID column 
contains the sample names in which the given variant was found. *denotes genes without disease association in 
MalaCards and OMIM.
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(MNX1, NINJ1, PER2, PHF20, PRSS56, RPH3A, and SBF1) in MalaCards and OMIM. See the detailed list con-
taining information about the individual variants in Table S2.
From these results, we can conclude that suicide is unlikely to be caused by a single dominantly inherited 
genetic allele.
Identification of potentially recessive loss-of-function rare variants. In this study, no HI homo- or 
hemizygote (X-linked) variants were identified; except the ZSCAN1 gene, which had two HI variants in the same 
GENE
SUICIDE SAMPLE 
COUNT
DOT1L*, TTC28* 4
TTC34*, SCLY*, SPHKAP*, SOGA1*, YES1 3
OTOG, PIK3R4*, SHISA6*, ZBTB49*, TATDN2*, DEDD2*, MAP3K14-AS1*, SMARCC1*, TXLNA*, DGKA*, 
C1QTNF7*, ZFC3H1*, BIK*, STC2*, GMEB2*, KLF7*,APLP2*, DCC, TNS1, PER2, MIXL1, KIAA1429, MCAM, 
LAMA3, MNX1, PRSS56, KIAA1549, SBF1, MRPL45, MYBPC1, PHF20, VAC14, RPH3A, NINJ1, REST
2
Table 3. List of putative dominant loss of function candidate genes where at least two samples had rare 
potentially damaging variants exclusively in the suicide samples.Each variant was a heterozygote and only 
counted if located in the same transcript of the gene. The GENE column contains the identified genes, the 
SAMPLE COUNT column contains the number of suicide samples in which a rare potentially damaging variant 
was found in the given genes. *denotes genes without disease association in MalaCards and OMIM.
GENE CHR POS REF ALT CONSEQUENCE SAMPLE ID
RP2 X 46696585 C T missense variant Y558
RP2 X 46696543 G C missense variant Y591
LINC00632* X 139795826 G A missense variant Y645
TSPAN6 X 99890198 C T missense variant BrA206
PBDC1* X 75397790 A C missense variant Y482
NR0B1 X 30326933 C A missense variant Y482
TIMP1 X 47444635 C G missense variant BIB82
TFE3 X 48888013 C T missense variant BrA206
TAB3* X 30864180 A G missense variant Y591
CXorf23* X 19948685 G A missense variant Y558
MAMLD1 X 149681090 A C missense variant Y591
STARD8 X 67937097 A G missense variant Y919
RBM10 X 47006890 G A missense variant Y919
MAP3K15* X 19398252 C T missense variant Y645
ALG13 X 111003183 G A missense variant Y787
ATP11C* X 138884497 G A missense variant & splice region variant Y166
TRO X 54956296 G A missense variant Y482
AFF2 X 148037417 G T missense variant BIB82
DMD X 31366742 C T missense variant Y482
OPHN1 X 67273643 T C missense variant BrA206
Table 5. Putative recessive loss of function X-linked candidate genes with hemizygous variants in male suicide 
victims.CHR and POS show the GRCh37 coordinate of the variant; the REF/ALT columns shows the reference 
and alternate alleles; the CONSEQUENCE is the type of the protein disruption; the SAMPLE ID column 
contains the sample name in which the given variants were found in heterozygote state. *denotes gene without 
disease association in MalaCards and OMIM.
GENE CHR POS REF ALT CONSEQUENCE SAMPLE ID
ZSCAN1* 19 58549663 TC T frameshift variant Y591
ZSCAN1* 19 58549495 G A stop-gain variant Y591
Table 4. Putative recessive loss of function candidate gene with two rare protein disruptive variants.CHR and 
POS show the GRCh37 coordinate of the variant; the REF/ALT columns shows the reference and alternate 
alleles; the CONSEQUENCE is the type of the protein disruption; the SAMPLE ID column contains the sample 
name in which the given variant was found in a heterozygote state. *denotes gene without disease association in 
MalaCards and OMIM.
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individual that complies with recessive inheritance. This gene encodes a zinc finger-domain transcription factor, 
which is expressed in the brain, but thus far has not been associated with any human disease (Table 4).
In the second part of this analysis, we also included MI variants in the study. We selected genes, where at least 
one suicide sample had an HI/MI variant in homo-, hemi- or compound heterozygous state. We excluded variants 
that were in the same allele, in the cases where we had phasing information. Only COL6A6 showed at least two 
heterozygote variants in three samples, all other genes had such variants in one sample only.
Among the 79 identified genes, 60 genes were on autosomal chromosome (Table S3). We found the following 
12 genes, which were associated with neurological disorders: DNAH5, CTTNBP2, TSC2, NAV2, TG, PARD3B, 
CREB1, KCNB1, MAN1B1, NSD1, RERE, and ERCC5.
We also identified 19 X-linked candidate genes with hemizygous MI variants in male suicide individuals that 
fit to our criteria, but only one of these (RP2 gene) had been found in two male suicide victims (Table 5). We 
identified four genes that had already been associated with neurological disorders (AFF2, ALG13, OPHN1, and 
RBM10).
Microsatellite analysis. STRs are composed of 2–6 bp DNA motifs that repeated approximately 5 to 50 
times. STRViper and lobSTR analyses were carried out to investigate the potential role of these microsatellites 
within the exonic, intronic, and UTR sequences, as well as whether in the proximal promoter regions these could 
serve as genetic factors in suicide. In this analysis, we tested the hypothesis of whether the length of the repeat 
region may be an important factor. The LobSTR-based method is capable of analysing the short repeat sequences 
(<100 bp), where the reads fully contained the repeat. As a result of this approach, we could not detect signifi-
cant differences in the lengths of STRs between the suicide and control groups. The STRviper approach is capa-
ble of analysing larger repeats37, but no single large STR expansion or contraction (as is the cause for example 
Huntington disease) were detected in any of the suicide samples. From this study, we can conclude that large 
STR-based variations do not support the monogenic disorder hypothesis. However, we mention here that longer 
repeats with minor variations cannot be examined with short-read sequencing.
Analysis of copy number variation. The high coverage of sequencing reads allowed us to analyse the 
CNV polymorphism. In this part of the study, we investigated 286,754 high coverage (average coverage >20-fold) 
regions. Wilcoxon Rank-Sum test with Bonferroni multiple hypothesis testing correlation did not reveal any 
significant differences in the copy number of the investigated regions between control and suicide samples; thus, 
this kind of polymorphism alone is unlikely be responsible for suicidal behaviour.
Gene network analysis. Of the 201 genes implicated by our analyses, 191 genes had an entry in the 
STRING database. 88 out of the 191 genes were interconnected; while 20 genes had interactions with experi-
mental evidence forming a network as shown in Figs S1 and S2. The biggest hub in this network was SMAD3.
The Enrichment Analysis function on the Gene Ontology (GO) website was used to identify gene sets from the 
obtained candidate genes, which cluster into gene networks. Four genes belonging to the transforming growth 
factor beta (TGF-β) signalling pathway have been found to be enriched (p = 0.0225; with α = 0.01 following 
Bonferroni correction) in the dataset obtained from the analysis of region-dependent accumulation of rare var-
iants. Genes NREP, SMAD3, HIPK2 and PRDM16 are all members of the TGF-β pathway and the regulation of 
Figure 1. NREP, HIPK2, PRDM16, SMAD3 and their roles in the canonical TGF-β signalling pathway. The 
region-dependent accumulation of rare variants dataset was significantly enriched in the genes connected to 
the TGF-β pathway. Highlighted are the four genes contained in the dataset. Interactions were drawn using 
Pathvisio 3.2.4.
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cellular response to TGF-β (Fig. 1). The SMAD3 is a transcriptional modulator, while the rest of the genes code for 
transcription factors. We have identified mutations in the 3′-UTRs of the SMAD3; HIPK2; and PRDM16 in 4–4 
subjects each. Mutations of the NREP gene are accumulated in the splice region in six subjects. Note that SMAD3 
is a hub protein with multiple interactions (Fig. S1), and that NREP directly acts on TGF-β.
Altogether, 15 suicide subjects had 18 variants, which may affect the function of the TGF-β pathway. The 
members of the TGF-β superfamily have been shown to play an important role in the formation of synapses and 
neural development38. The TGF-β1 itself was first implicated in the pathogenesis of depression when Myint and 
colleagues39 found significantly lower levels of this protein in the blood of patients diagnosed with MDD than in 
the control group. Since then numerous studies have confirmed the connection between MDD and TGF-β40–43. 
Studies were able to associate low levels of TGF-β1 with MDD but they have failed to associate TGF-β with sui-
cidal behaviour. However, Lee and Kim44 examined attempted suicide, while O’Donovan and colleagues45 inves-
tigated suicide ideation, in contrast to our work, in which we investigated completed suicide. Furthermore, these 
reports examined the TGF-β itself, while our work detected four other genes of the TGF-β pathway as candidates 
for suicide. We did not obtain a significant enrichment of genes within a gene network for the rest of the datasets.
Detection of viral DNA in the brain. We took advantage of the off-target reads and analysed them for 
the presence of virus sequences. We could detect human herpes virus 6 (HHV6) in the autopsy brain samples of 
suicide victims (HHV6B in two victims and HHV6A in one of the HHV6B-infected individuals); these sequences 
were not identified in the controls. The herpesviruses have been considered to play a role in the development of 
various neurological diseases including multiple sclerosis46, Parkinson’s disease, Alzheimer’s disease47 and epi-
lepsy48, 49. However, due to the low sample size and frequency of infection, we cannot state for sure that HHV6 
infection is a risk factor for suicide.
Discussion
In this report, we performed WES analysis in brain samples of suicide victims, who suffered from MDD and 
control subjects who died from other causes. We searched for rare minor alleles found only in the suicide victims 
and not in our controls nor in the available human genome/exome databases. We also analysed the genes and 
intragenic sequences for potential multiple variants, the differences in the lengths of microsatellites and the CNV 
of the covered genomic regions. Additionally, gene network analysis of the candidate genes was also carried out. 
We also investigated the presence of potentially pathogenic viruses in the brain tissues. The effect of sampling 
bias was minimized by using gender-ratio-matched ethnic group (Hungarian) controls. In our suicide cohort, the 
male victims chose more extreme method of suicide (hanging or jumping; 14 out of 15 victims), while females 
chose less extreme means, namely drug overdose (5 out of 8 victims).
This genomic analysis focuses on the accumulation of genetic variants within the genes instead of individual 
variants. From our results, we can conclude that suicide is unlikely caused by a single gene, instead, it may be 
either an umbrella disease-like disorder caused by multiple high-penetrance genes, or it may be determined by 
the concerted action of multiple genes and the environment. We detected rare genetic variants, which potentially 
could be the causes of suicide. We emphasize the potential significance of the three calcium ion channel genes 
(CACNA1B, -1C, and -2D4), which we identified in two different analyses. The CACNA1A, another calcium 
channel gene, has also been proposed by others as a candidate gene for MDD35. This report also identified several 
candidate genes that have not been associated with any diseases until now. Additionally, our study also revealed 
that the TGF-β signalling pathway may play a causative role in the completed suicide (Fig. 1), which is a confir-
mation of earlier studies that proposed a role for TGF-β in MDD40–44. Members of the TGF-β superfamily have 
been shown to play an important role in the formation of synapses and neural development in invertebrates50, 51  
and in vertebrates38, 52 as well. Alteration in TGF-β signalling may also shift the balance of pro-inflammatory 
and anti-inflammatory cytokines, as proposed in MDD39. However, since no other controls (non-suicide MDD 
patients and non-MDD suicide victims) were used in this study, the identified candidate genes and the TGF-β 
signalling pathway may be general genetic factors for the depression or for the suicide, instead of having potential 
exclusive roles for the completed suicide in MDD patients.
Materials and Methods
Clinical samples and ethical statements. Brains from suicide victims (n = 23; 15 males and eight 
female) and from control participants (n = 21; 14 males and seven females) were used for whole-exome sequenc-
ing. Samples were taken from the occipital cortex, cerebellar cortex and somatomotor cortex of individuals. All 
patients died suddenly from causes not directly involving any CNS diseases. Tissue samples were obtained by 
autopsy at the Department of Forensic Medicine of the Semmelweis University Medical School. In the case of 
suicide victims, a psychiatric diagnosis of MDD was on record. These were done and/or confirmed by experi-
enced psychiatrists on the basis of criteria defined in the fourth edition of Diagnostic and Statistical Manual of 
Mental Disorders. Suicide victims died by hanging (n = 16), drug overdose (n = 6), or jump from height (n = 1). 
Causes of death in control subjects were the following: acute heart failure (n = 4), myocardial infarction (n = 6), 
cardiorespiratory insufficiency (n = 4), chronic hepatitis (n = 2), chronic bronchitis (n = 1), Alzheimer’s disease 
(n = 2), acute cardiopulmonary insufficiency (n = 1), and stroke (n = 1). Examination of medical records of con-
trol subjects at the autopsy confirmed the absence of psychiatric illness within the past 10 years. All of the con-
trols and suicide victims were Caucasians of Hungarian ethnicity (Budapest region). Harvesting of tissues was 
approved by the local ethics committee53. Data were analysed anonymously.
Whole exome sequencing. Whole-exome sequencing was carried out in DNAs of 23 suicide victims and 
21 controls using post mortem brain tissues as a source. Genomic DNA samples were purified from the cortex 
regions using the DNeasy Blood and Tissue Kit (Qiagen) according to the manufacturer’s protocol. (30 mg tissue 
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was used from each sample for the DNA extraction.) The qualified genomic DNA (200 ng from each sample) 
were fragmented by Covaris technology with resultant library fragments of 200–450 bp. Whole exome sequenc-
ing was performed as previously described (Chen et al., 2013) with slight modifications. In brief, whole exome 
enrichment was performed with the Agilent SureSelect Human All Exon V5+UTRs kit (Agilent Technologies, 
Santa Clara, CA), following the kit’s recommendations and sequenced with the Illumina HiSeq. 2000 sequencer 
(Illumina, San Diego, CA) to generate 100 bp-paired end reads. BWA MEM (version 0.7.9a-r786) was used to 
align reads to the GRCh37 reference genome. Genome Analysis Toolkit (GATK) HaplotypeCaller (version 3.5) 
best practices54 were used to generate final quality recalibrated BAM files for downstream analysis and variant 
calling. SnpEff55 (version 4.3) with GRCh37.75 data set was used for annotating variants. We obtained very high 
coverage per base position in both cohorts; in the Hungarian control cohort 96.3–97.5% (quartiles) of target 
regions had higher than 20-fold and 81.6–91.6% of target regions had higher than 40-fold coverage. In the suicide 
cohort these values were 95.4–97.5% for 20-fold and 82.8–90.5% for 40-fold coverage, respectively. We obtained 
on average ~130,000 variants per sample using the SureSelect V5 Plus all Exon kit for the exome sequencing. We 
identified 442,270 unique variants in the suicide and control cohorts altogether. In the study of biallelic variants, 
we excluded 11,634 multiallelic-, 2,344 pseudogenic-, and 6,234 refseq errors, as well as, 27,565 low complexity-, 
32,025 uncertain-, and 68,015 low-depth variants. Among the remaining 294,453 high quality, biallelic variants 
30,206 had no MAF values and 264,247 biallelic variants had known MAF values in the public (dbSNP and/or 
EVS) databases.
Analysis of biallelic variants. To filter out high quality biallelic variants that follow HWE, we used the 
following criteria for the exclusion: variants failed PASS filter for >10% of samples; variants where coverage were 
<10x for >10% of samples; variants in low complexity repetitive regions were excluded (the analysis was based 
on the Dust score of flanking 15 bases of the reference sequence 5′ and 3′ around the variant); technical errors 
(wetlab or bioinformatic) and pseudogenic variants that violated HW equilibrium in controls. We defined com-
mon variants that had minor allele frequency (MAF) in dbSNP (build 146 GRCh37); ~6,000 exome data of 
Exome Variant Server (EVS); ~60,000 exome data of ExAC database; or it was found in more than two samples in 
Hungarian control group. We investigated rare variants with MAF < 1/5,000 values in the public databases 
(dbSNP, EVS, ExAC), assuming dominant, and MAF < 1/ 5,000 , assuming recessive Mendelian inheritance. The 
following two scenarios were tested: in the gain-of-function scenario, we tried to find putative regulatory or cod-
ing regions of the genes exhibiting region-specific accumulation of mutations in the suicide cohort but not in the 
control group; in the loss-of-function scenario, we assumed random distribution for the potentially 
protein-disrupting variants (high- or moderate-impact (MI) mutations) throughout the coding and UTR regions 
of the genes.
Analysis of rare variants - region dependent accumulation. For this analysis, we created a bed coordinate list 
based on the original SureSelect V5 All exon + UTR Plus target region that contained all 5′ UTR, 5′ flanking 
intronic, exonic, 3′ flanking intronic, and 3′ UTR regions separately. We investigated all regions searching for the 
accumulation of rare (AF < 1/5000) variants in the control and the suicide cohorts. Similarly to the approach that 
is used at ExAC56 for the classification of genes by the ratios of expected and observed synonymous and poten-
tially damaging mutations, for each bed coordinate the count of rare variants was determined for both control and 
suicide cohorts. The analysed regions have been ranked on the basis of accumulation differences in rare variants 
between the control (expected) and suicide (observed) cohorts. Assuming random distribution of rare variants 
Monte Carlo simulation showed that the chance of having at least 4 rare variants (out of 14,393 rare variants in the 
suicide cohort) in any region (594,910 regions in total) is approximately 1%. Thus, a region with 4 or more rare 
variants observed in suicide cohort compared to the controls was considered a candidate.
Analysis of rare variants - Loss-of-function – putative dominant mutation. Based on SnpEff annotation of variants 
we selected rare variants that had HI or MI in any of the transcripts of genes covered in the exome kit (see SnpEff 
classification); those that had MAF < 1/5000 (assuming ~1:5000 incidence of suicide in Hungary) and more than 
two suicide patients had at least one of such variant in the same transcript. We also selected all HI variants in 
the cohort of suicide patients. From both lists we excluded bogus transcripts (no START codon, multiple STOP 
codons, incomplete transcript) and those transcripts that had any high- impact variant in public databases or in 
Hungarian controls that had MAF higher than 1/5000.
Analysis of Low-frequency variants - Loss-of-function – putative recessive mutation. Based on SnpEff annotation 
of variants we selected rare variants that had HI or MI in any of the transcripts of genes covered in the exome kit; 
had MAF < 1/71 (considering ~1:5000 incidence in Hungary, and recessive/homozygote/p2/frequency) and more 
than two suicide patients had at least two (or one homo- or hemizygote) of such variants in the same transcript. 
Furthermore, we excluded those variants that were located in the same allele, where we had phasing information 
(variant distance <100 bp read length). We selected transcripts which contained homozygote, hemizygote or 
compound heterozygote HI variants (compound heterozygosity: both alleles are mutated but at different loca-
tions). We also created a list where at least two HI heterozygote variants (or one homo-, hemizygote) were found 
in the same transcript in any of the suicide patients. From both lists we excluded bogus transcripts (no START 
codon, multiple STOP codons, incomplete transcript) and those transcripts that had any HI variant in public 
databases or in Hungarian controls that had MAF higher than 1/71.
Microsatellite analysis. We used STRViper37 to identify possible large STR expansions or contractions and 
lobSTR (version 3.0.2) according to its best practice guides for exome data analysis57 to calculate exact STR counts 
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of smaller repeats that were entirely spanned by the reads. STR counts of suicide and control were analysed by 
Wilcoxon Rank-Sum test with Bonferroni multiple hypothesis test correction. Wilcoxon-Mann-Whitney power 
analysis (alpha = 1.472e-4, SD = 1.07) showed that at the given sample size only large repeat differences (two or 
more repeats) between the two cohorts could be statistically analysed.
Analysis of copy number variation. In this analysis, we first refined the target regions specified in the 
original SureSelect V5 All exon + UTR Plus target region to contain only the actual high coverage BED coor-
dinates from the empirical sequence data of the control group using “samtools depth” algorithm (avg coverage 
>20x). “Samtools bedcov” algorithm has been applied on the high coverage BED coordinates identified in the 
previous step in order to calculate the coverage of sequencing reads for individual regions. Coverage data was 
normalised by the total GRCh37 mapped reads for each individuals and regions. Finally, matrix of 286,754 × 23 
and 286,754 × 21 region/coverage data were obtained for the suicide and control groups, respectively. Due to 
the possibility of biological CNV variation, the more robust Wilcoxon-Mann-Whitney test has been applied for 
data and power analysis and to calculate the p values. Power analysis showed that at 0.95 power, alpha = 1.74e-7 
(multiple hypothesis test correction to 286,754 regions), considering 50 percent coverage change between the two 
groups, 19 control and 19 suicide samples (Wilcoxon-Mann-Whitney test, with SD = 0.17) are needed to reveal 
significant differences.
Gene network analysis. All the genes implicated by our analyses were considered for gene network anal-
ysis. The STRING database was used to search for experimentally proven interactions between our candidate 
genes. In order to determine whether genes connected to suicidal behaviour are significantly enriched in a gene 
network, we used the Enrichment Analysis function on the Gene Ontology (GO) website (www.geneontology.
org)58, which combines the GO database with the PANTHER database59. We conducted separate searches for 
each of the four sets of genes (Table S4) identified as potential genetic factors for suicide. We also conducted an 
enrichment analysis containing all the genes in the four datasets.
Detection of viruses in the brain. In this analysis, we extracted all the reads that were not mapped to 
human GRCh37 reference sequence in each sample from the corresponding BAM files. Using a custom script, 
we converted them to a multiline FASTA file where the QNAME (See SAM file specification) field was used as 
sequence ID and the sequence was extracted from each of the unmapped reads. Standalone BLAT60 was used to 
align the FASTA files of each sample to the NCBI curated all viral genomes (ftp://ftp.ncbi.nlm.nih.gov/refseq/
release/viral/). BLAT hits with >90 bp length and >95% identity were filtered out and summarized for suicide 
and control cohorts using custom scripts.
Data Availability. Sequenced data were deposited at the Sequence Read Archive (SRA) under BioProject 
SUB2335490).
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